Angle's Maiden M&A Fills Gaps In Liquid Biopsy Solution

By acquiring Axela Inc, liquid biopsy specialist Angle PLC will now be able to pair the Canadian firm's gene expression measurement technology with its Parsortix circulating tumor cell harvesting system. Angle will finance this transaction with the proceeds it expects to raise from a proposed £12.2m share placement.

Digital illustration of Cancer cell in colour background

Angle PLC is looking to offer a more complete, end-to-end liquid biopsy solution – from circulating tumor cell (CTC) capture to downstream analysis of these target cells – following an agreement to acquire Axela Inc., a specialist in gene expression measurement.

Angle's Parsortix system, which is CE marked for clinical use and is currently being trialed in several studies for different...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Oncology

More from Device Area